Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox Launch in the UK and Pricing Approval for Ireland

Jan 27, 2016Mark EdwardsNews

27 January 2016

ASX ANNOUNCEMENT

Penthrox Launch in the UK and Pricing Approval for Ireland

Medical Developments International Limited (ASX: MVP) is delighted to announce that its fast acting, category leading non-narcotic analgesic, Penthrox, was launched in the UK by Galen Limited on 25 January 2016.

In addition to the launch in the UK, MVP is delighted to announce Penthrox has received full pricing reimbursement approval from the Irish Medicine’s Board, which is another significant achievement.

For more information please refer to the following link ASX Announcement_Penthrox Launch in the UK and Pricing Approval for Ireland

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter